China's innovative drugs are selling like hotcakes overseas! Akeso Biopharma surges 10%; Is China's biotech industry crushing Europe and America? [CSOP ETF Market Update]
The hot wave of the Hong Kong stock innovative drug market continues, with frequent overseas BD transactions driving the Hong Kong stock innovative drug sector to soar by more than 60% this year. On July 17, the innovative drug sector continued its strong trend, with the Solactive China Healthcare Innovation Index surging nearly 3%, once again refreshing its historical high. $AKESO(09926.HK) surged more than 10% intraday, and BeiGene rose more than 5%.
According to insiders, British pharmaceutical giant $AstraZeneca PLC(AZN.UK) is in talks with American biotechnology company Summit Therapeutics for a licensing agreement worth up to $15 billion, aiming to acquire a lung cancer drug in the experimental stage from the latter.
康方生物 is the "inventor" of this drug— in 2022, 康方生物 sold the overseas rights of this drug to Summit for up to $5 billion. Now, Summit plans to resell it to 阿斯利康 at a higher price, and the market speculates that 康方生物 may gain additional profits from the resale transaction, directly stimulating a surge in stock price.
Bloomberg's exclusive analysis shows that last year, the number of new drugs for diseases such as cancer and weight loss entering the research and development stage in China surged to more than 1,250, far exceeding the EU level and approaching the 1,440 in the United States. This data, from pharmaceutical intelligence solution provider Nostra, directly reveals a significant shift in the global focus of medical innovation.
The rise of Chinese innovative drugs is being "voted" with real money. Nostra pointed out that last year, China's share in global pharmaceutical licensing transactions soared to 18%, and $HENGRUI PHARMA(01276.HK) and 20 other Chinese companies have entered the top 50 in global innovative drug research and development.
The progress of Chinese biotechnology is expected to become a key area of competition among major powers, like artificial intelligence and electric vehicles. Goldman Sachs previously analyzed that the overall market value of Chinese biotechnology companies is only 14%-15% of their American counterparts, but their share in global innovation contribution has approached 33%. This means that the Chinese innovative drug sector is still in a "value depression," and the global capital repricing has just begun.
Given the significant progress and international recognition of China's pharmaceutical industry, investors can pay attention to $CSOP HEALTHCARE(03174.HK)—this product covers innovative pharmaceutical companies such as 康方生物， capturing the innovation dividends of the pharmaceutical industry.
Important Statement
The products described in this document are recognized by the Securities and Futures Commission of Hong Kong ("SFC"). Such recognition does not imply official recommendation by the SFC.
This document is for general reference only and does not constitute investment or any other advice, nor should it be considered an offer or solicitation to invest in any investment product. For investment advice, please consult your professional legal, tax, and financial advisors.
Investment involves risks. Past performance data does not predict future performance. Investors should carefully read the sales documents and product data summaries of the relevant funds to obtain further information, including the product features and all risk factors contained therein. Investors should not make investment decisions based solely on this document. This document is not applicable in jurisdictions where its distribution or dissemination is prohibited.
This document is not legally binding. South East Asia Asset Management Limited is not responsible for this document and states that it will not be liable for any loss arising from or in reliance on any part of the content of this document. This document does not grant the recipient any copyright or intellectual property rights (whether directly, indirectly, or implied) to use the information contained herein. Without the written consent of South East Asia, no data or any part of this document may be copied, distributed, or reproduced.
The products described in this document may face regional, market, industry, or investment tool concentration risks. Compared to funds with more diversified investment portfolios, the value fluctuations of the products described in this document may be greater.
For the index provider's disclaimer, please refer to the offering documents of the relevant funds. This document is prepared by South East Asia and has not been reviewed by the SFC.
Issuer: South East Asia Asset Management Limited
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
